Innovative treatments for multiple myeloma in adults who are not candidates for stem transplantation
DOI:
https://doi.org/10.18203/2320-6012.ijrms20243457Keywords:
Multiple myeloma, Treatment, Diagnosis, Innovation, SurvivalAbstract
In the reviewed article, we evaluated the different innovative therapeutic options for the treatment of multiple myeloma in patients who are not candidates for stem cell transplantation. Multiple myeloma (MM) is a malignant neoplasm whose incidence is increasing in developed countries. It represents around 1% of neoplastic diseases and 13% of hematologic cancers. It arises from an asymptomatic proliferation of premalignant monoclonal plasma cells derived from B cells after they pass through the germinal center stage in various genetic steps and microenvironmental changes. Although in this study we discuss various therapeutic options that seem promising, we must keep in mind that these still require further research for their application in order to reduce the adverse effects that some of them may present.
Metrics
References
Espinosa Trigo M. New treatments under study for multiple myeloma. (Unpublished Final Degree Project). University of Seville, Seville. 2022. Available at: https://idus.us.es/items/821dbbd4-fec5-49f9-8404-d877902eea11. Accessed on 12 August 2024.
Rafae A, Van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. The Oncologist, 2024;29(3):200-12.
Munshi NC, Longo DL, Anderson KC. Chapter 107: Plasma Cell Disorders. In: Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison's Principles of Internal Medicine, 20th Edition. Volume 2. New York: McGraw-Hill. 2016;710-9.
Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci. 2021;9(1):3.
Abello V, Omaña P, Daza J. Anticuerpos biespecíficos en mieloma múltiple: un nuevo paradigma. Medicina. 2023;45(4):656-71.
Espinoza JR, Sosa A, Labardini J. Chapter 84: Multiple Myeloma. In: Gómez A, Ñamendys Silva S, Meneses García A. Oncology Handbook, 6th Edition. México: McGraw-Hill. 2017;450-74.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380:2104-15.
Meletios A, Dominik D, Sebastian G, Philippe M, Naoki T, Mitsuo H, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018;379:1811-22.
Dimopoulos, M.A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Moreau, P. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319-31.
Cho SH, Shin HJ, Jung KS, Kim Y. Dose Adjustment Helps Obtain Better Outcomes in Multiple Myeloma Patients with Bortezomib, Melphalan, and Prednisolone (VMP) Treatment. Turk J Haematol. 2019;36(2):106-11.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al; ALCYONE Trial Investigators. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018;378(6):518-28.
Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, et al. Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902). Ann Hematol. 2016;95:921-9.
Zarone MR, Misso G, Grimaldi A, Zappavigna S, Russo M, Amler E, et al. Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. Sci Rep. 2017;7(1):17949.
Ubels J, Sonneveld P, van Beers EH, Broijl A, van Vliet MH, de Ridder J. Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. Nat Commun. 2018;9(1):2943.
Cao Y, Wang N, Liang Z, Xie J, Wang S, Lin T, et al. Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. Clin Lymphoma Myeloma Leukemia. 2019;19(8):478-88.
Legarda MA, Cejalvo MJ, de la Rubia J. Recent advances in the treatment of patients with multiple myeloma. Cancers. 2020;12(12):3576.
Chen Y, Lairson D, Chan W, Du X. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma. Ann Hematol. 2018;97:851-63.
Weisel K. Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date. Onco Targets Ther. 2016;9:6037-48.
Cantó PA, Herraiz MA, de la Rubia Comos J. Immunotherapy in multiple myeloma. Clin Med. 2024;1:1.
Kumar V, Abbas AK, Aster JC. Structural and functional pathology. In: Kumar V, Abbas AK, Aster JC. Robbins y Cotran Patología estructural y funcional. 9ª edition. Barcelona España: Elsevier. 2015;579-628.
